奥瑞珠单抗：全球首次批准。
Ocrelizumab: First Global Approval.
机构信息
Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand.
出版信息
Drugs. 2017 Jun;77(9):1035-1041. doi: 10.1007/s40265-017-0757-6.
Ocrelizumab (Ocrevus™) is a humanised anti-CD20 monoclonal antibody that has been developed by Genentech, Inc. (a subsidiary of Roche) for the treatment of multiple sclerosis (MS). The drug is designed to deplete B cells, which play an important role in the pathogenesis of MS. In March 2017, ocrelizumab was approved in the USA for the treatment of patients with relapsing or primary progressive forms of MS; currently, it is awaiting approval in the EU for the same indications. This article summarizes the milestones in the development of ocrelizumab leading to its first global approval for the treatment of MS.
奥瑞珠单抗（Ocrevus™）是一种由罗氏（Roche）旗下基因泰克公司（Genentech, Inc.）开发的人源化抗 CD20 单克隆抗体，用于治疗多发性硬化症（MS）。该药物旨在耗尽 B 细胞，B 细胞在 MS 的发病机制中起着重要作用。2017 年 3 月，奥瑞珠单抗在美国获批用于治疗复发型或原发性进展型多发性硬化症患者；目前，该药正在欧盟等待批准用于相同的适应证。本文总结了奥瑞珠单抗的开发历程中的重要里程碑，这些里程碑促使该药在全球范围内首次获批用于治疗多发性硬化症。
Zotero 插件